+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers

  • PDF Icon


  • 23 Pages
  • July 2018
  • Region: Global
  • BCC Research
  • ID: 4600692
UP TO OFF until Aug 31st 2033

The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

The Report Includes:-

  • An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
  • Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
  • A brief examination of the patent landscape
  • Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
  • Coverage of a number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
  • Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth

Membership Price:

Contact us for membership pricing.

Table of Contents

1 Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes
  • Key Findings
  • Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments
  • Adoptive Cell Transfer (ACT) and Therapeutic TILs
  • Ground-Breaking Management of Advanced Metastatic Breast Cancer
  • Successful Advances in TILs Therapies for Cholangiocarcinoma
  • Hope for Immunotherapy Treatments of Gastrointestinal Cancers
  • Limitations of ACT and Therapeutic TILs
  • Overcoming the Limitations of ACT and Therapeutic TILs
  • Expanding Clinical Trial Portfolio
  • Complexities of the TILs Patent Landscape
  • What's Next for TILs?
  • Outlook and Implications

2 References3 A Note from the Editor4 Analyst Credentials
List of Tables
Table 1: Overview of PD-1/PD-L1 inhibitors, Mechanisms of Action, Trial Designations and Approved Companion Diagnostics
Table 2: Commonly Used Acronyms Associated with Adoptive Transfer of Autologous TILs Therapy
List of Figures
Figure 1: Schematic of Adoptive Cell Transfer (ACT) Therapies
Figure 2: Schematic of Tumor-Infiltrating Lymphocytes (TILs) Therapies
Figure 3: Number of Clinical Trials Incorporating Tumor-Infiltrating Lymphocytes (TILs) Activity, by Phase and Year, by Study Start Date, 2005-2018*
Figure 4: Clinical Pipeline Iovance Biotherapeutics